The upregulation of CDK4 triggers the development of non-alcoholic fatty liver disease (NFALD), which leads to the phosphorylation of C/EBPα on Ser193 and the formation of C/EBPα-p300 complexes, resulting in hepatic steatosis, fibrosis, and liver cancer. Here, EP300 is linked to metabolic dysfunction-associated steatotic liver disease.